Skin aging

Vbeam Pro will be unveiled at the 2025 Annual Meeting of American Society for Laser Medicine and Surgery (ASLMS) MARLBOROUGH, Mass., April 24, 2025 /PRNewswire/ -- Candela Corporation, a global leader in energy-based medical aesthetics, proudly announced the launch of the Vbeam Pro platform at the 2025 Annual Meeting of the American Society for Laser Medicine and Surgery (ASLMS), held in Orlando, FL. Representing the most significant advancement in Candela's four-decades of clinical leadership in pulsed dye laser (PDL) technology, the Vbeam Pro device sets a new market standard for the treatment of vascular and dermatologic conditions. Continue Reading Vbeam Pro Logo Vbeam Pro Device The Vbeam Pro device is the only vascular laser FDA-cleared for use in pediatric patients and combines an advanced 595 nm pulsed dye laser with a 1064 nm Nd:YAG wavelength to offer unmatched precision, accuracy, and treatment versatility. The platform is designed to effectively treat a broad spectrum of skin conditions, including rosacea, port-wine stains, acne, leg veins, spider veins, scars, benign pigmented lesions, wrinkles, warts, stretch marks, and photoaging. "The Vbeam Pro system is a transformative evolution in pulsed dye laser technology," says Dr. Roy Geronemus, Clinical Professor in the Department of Dermatology at NYU Grossman School of Medicine and Medical Director of the Vascular Birthmarks Foundation. "The clinical results are remarkably consistent, and patients are experiencing enhanced outcomes compared to earlier-generation systems," he adds. With its dual wavelengths and 30% tighter energy delivery control, the Vbeam Pro laser offers a new level of efficacy and efficiency for clinicians treating patients across all Fitzpatrick skin types (I–VI). The platform also features optimized dye life and an enhanced user interface, delivering a superior treatment experience for both practitioners and patients. Backed by rigorous clinical research, the Vbeam Pro laser has demonstrated: 20% improved clearance of treated lesions¹ 50% faster treatment times² 20% reduction in reported patient discomfort³ "Reinforcing Candela's commitment to scientific rigor, the Vbeam Pro system underwent extensive clinical evaluation at leading dermatology practices across the United States," says Konika Patel Schallen, MD, Senior Vice President of Clinical Operations and Medical Director at Candela. "We put the platform through stringent testing, using it in busy clinical environments on a wide variety of skin types and conditions. We are excited about the feedback from our dermatology users on enhancing patient outcomes and treatment efficiency." she concludes. "Building on Candela's longstanding clinical leadership, the introduction of the Vbeam Pro system represents a major leap forward in the treatment of vascular and other skin conditions," said Geoffrey Crouse, Chief Executive Officer of Candela. "This milestone launch reflects our unwavering commitment to continuous innovation, rooted in proven science, consistent clinical outcomes, and trusted partnerships with both healthcare providers and patients." Attendees of ASLMS 2025 are invited to experience the Vbeam Pro device by visiting Candela at Booth #321. For more information, please visit: candelamedical.com 1. Compared to Vbeam Perfecta; Vbeam 595 nm output Accuracy and Precision data on file 2. Supported by early LCR participant treatment feedback 3. Data from LCR sites relative to Perfecta 4. Based on patient reports from LCR sites relative to prior Vbeam systems Media Contact: Lindsey Hans, [email protected] SOURCE CANDELA WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

The 50IU, 100IU and 200IU formulations cover aesthetic and therapeutic indicatons The strong partnership with Medica Group will boost Hugel's expansion in the MENA SEOUL, South Korea, Jan. 21, 2025 /PRNewswire/ -- Hugel Inc., a leading global medical aesthetics company chaired by Suk Cha, said on Wednesday it received approval for its botulinum toxin Botulax with aesthetic and therapeutic applications from the United Arab Emirates (UAE) on January 20, achieving a significant milestone for the company's global expansion. The approval of Botulax in 50IU, 100IU, and 200IU covers five aesthetic and medical indications: eyelid spasm; crow's feet; glabellar lines; upper extremity muscle spasticity after stroke; and cerebral palsy adduction deformity in children. The company plans to officially release the toxin Botulax in the Middle East and North Africa (MENA) at the end of April. Medica Group, Hugel's aesthetic toxin distribution partner headquartered in the UAE with branches in Saudi Arabia and Lebanon, will lead the sales in MENA with its strong regional networks. Hugel will accelerate its market expansion with unique sales and marketing strategies in the region. Building on the success of its hyaluronic acid dermal filler Revolax, which won approval in the UAE in 2023, the company will strengthen its comprehensive medical aesthetic portfolios. The MENA represents one of the fastest-growing markets for medical aesthetics, driven by robust economic growth, favorable demographic trends, increasing social media engagement, and rising demand for aesthetic treatments. Hugel is preparing for the approval process of its toxin in other MENA countries such as Saudi Arabia and Qatar. "We are excited about the growth potential in the MENA market with the approval for Botulax with aesthetic and therapeutic indications. Hugel will expand its business through the high quality of the toxin and Medica Group's comprehensive understanding of the market and its active partnerships combined with the regional networks," a Hugel official said. About Hugel Established in 2001, Hugel is a global leader in medical aesthetics, specializing in the production of injectables for skin rejuvenation, including botulinum toxin, hyaluronic acid fillers, and skin boosters, as well as absorbable sutures and cosmetic products. As the market leader in injectable aesthetics in South Korea, Hugel is the only South Korean company with regulatory approvals in the world's three largest botulinum toxin markets: the US, China, and Europe. With a proven track record of safety and quality, Hugel is deeply committed to advancing the industry through robust medical affairs, comprehensive training programs, and dynamic industry forums. Over the past 20 years, the company has built a presence in approximately 70 countries and operates eight global subsidiaries across South Korea, the US, Australia, Canada, Taiwan, China, Hong Kong, and Singapore. Leveraging strong industry momentum, Hugel is poised for continued growth and global market expansion. Contact: Jihyun Kim, Manager of the PR Team, Hugel [email protected] SOURCE Hugel WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

CHONGQING, China, Sept. 25, 2024 /PRNewswire/ -- MingMed Biotechnology, an innovative company focused on the in-house discovery and development of novel drugs, recently announced that its partially owned subsidiary, Claruvis Pharmaceutical Co., has received approval from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for YY003, the world's first liquid formulation of recombinant BoNT/A, packaged in a pre-filled syringe, developed for the treatment of glabellar lines. "We are thrilled to receive FDA approval to advance the novel liquid formulation of rBoNT/A (YY003) into clinical development. This liquid-formulated recombinant BoNT/A, delivered via a prefilled device, represents a safer and more convenient option for users. The combination of a super-pure, highly effective product and its ease-of-use design offers BoNT/A users an optimized solution," said Dr. Wu Yang, Chief Scientific Officer of Claruvis, who has over 20 years of experience in botulinum toxin research and development. Claruvis Pharmaceutical, one of the few pioneering biotech companies in China, has developed the world's first recombinant BoNT/A product to reach clinical studies. The company recently completed its Phase III clinical trial for treatment of medium to severe glabellar lines and achieved all the study end points. The efficacy, safety and immunogenicity profiles demonstrated in the trial have set a remarkable milestone in the field of cosmetical use of BoNTs. On September 14th, the company has also successfully dosed the first patient in a phase II clinical trial for treatment of adult upper arm spasm in China, setting another new world record utilizing recombinant BoNT/A for the therapeutic indication. The company has started its first Biologics License Application (BLA) in China, backed by a comprehensive set of successful Phase I, II, and III clinical results. Dr. Yang added, "We believe the FDA's approval of YY003 for clinical evaluation is a significant milestone towards launching a high-quality product in the Botulinum toxin market." About MingMed MingMed Biotechnology Co., Ltd. is an innovative company dedicated to the in-house discovery and development of novel drugs that address global unmet medical needs. Our R&D team is led by global top-notch scientists and specialists. Leveraging our research and development capabilities and efficient operations, we have built an internally developed product portfolio with a diverse yet synergistic suite of four major therapeutic areas, namely recombinant botulinum toxin, ophthalmic drugs, immuno-oncology drugs and pet immune drugs. Our product pipelines include a number of first-in-class drug candidates, and the major products have moved forward to commercialization. About Claruvis Pharmaceutical Claruvis, a non-wholly owned subsidiary of MingMed Biotechnology, is strategically focus on the development, production and commercialization of botulinum toxin products utilizing recombinant protein technology. The R&D team is formed by top-notch global scientists and senior American Chinese scholars with in-depth knowledge and experience in botulinum toxin products. Marking a significant milestone, Claruvis has pioneered the development of the world's first recombinant type A BoNT product on a self-developed R&D platform. Excellent operational capability supported by a globally competitive R&D platform will continue to drive Claruvis' innovation and fast development in the rBoNT area to address the vast number of unmet aesthetic and therapeutic medical needs worldwide. Contact: [email protected] SOURCE MingMed Biotechnology WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED